[go: up one dir, main page]

AU2000280405A1 - Targeting cells having mad2 mutation for treatment and/or prevention of disease - Google Patents

Targeting cells having mad2 mutation for treatment and/or prevention of disease

Info

Publication number
AU2000280405A1
AU2000280405A1 AU2000280405A AU2000280405A AU2000280405A1 AU 2000280405 A1 AU2000280405 A1 AU 2000280405A1 AU 2000280405 A AU2000280405 A AU 2000280405A AU 2000280405 A AU2000280405 A AU 2000280405A AU 2000280405 A1 AU2000280405 A1 AU 2000280405A1
Authority
AU
Australia
Prior art keywords
mad2
mutation
disease
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2000280405A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2000280405A1 publication Critical patent/AU2000280405A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
AU2000280405A 2000-10-03 2000-10-03 Targeting cells having mad2 mutation for treatment and/or prevention of disease Withdrawn AU2000280405A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/027462 WO2003044525A1 (en) 2000-10-03 2000-10-03 Targeting cells having mad2 mutation for treatment and/or prevention of disease

Publications (1)

Publication Number Publication Date
AU2000280405A1 true AU2000280405A1 (en) 2003-06-10

Family

ID=21741849

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2000280405A Withdrawn AU2000280405A1 (en) 2000-10-03 2000-10-03 Targeting cells having mad2 mutation for treatment and/or prevention of disease
AU78597/00A Abandoned AU7859700A (en) 2000-10-03 2000-10-03 Targeting cells having MAD2 mutation for treatment and/or prevention of disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU78597/00A Abandoned AU7859700A (en) 2000-10-03 2000-10-03 Targeting cells having MAD2 mutation for treatment and/or prevention of disease

Country Status (4)

Country Link
EP (1) EP1334358A1 (en)
JP (1) JP2005509447A (en)
AU (2) AU2000280405A1 (en)
WO (1) WO2003044525A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2906532B1 (en) * 2006-09-28 2008-12-12 Biomerieux Sa NEW OLIGONUCLEOTIDE BRAND
BRPI0920297A2 (en) * 2008-10-24 2016-08-02 Magnachem Int Lab Inc method for selecting pharmaceutically active compounds and pharmaceutically acceptable compound
JPWO2011083830A1 (en) * 2010-01-06 2013-05-16 学校法人関西文理総合学園 Novel anticancer agent and screening method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6591596A (en) * 1995-08-01 1997-02-26 Sloan-Kettering Institute For Cancer Research Gene encoding the human homolog of mad2

Also Published As

Publication number Publication date
JP2005509447A (en) 2005-04-14
EP1334358A1 (en) 2003-08-13
WO2003044525A1 (en) 2003-05-30
AU7859700A (en) 2003-06-10

Similar Documents

Publication Publication Date Title
GB2368794B (en) Prevention and treatment of amyloidogenic disease
HUP0201205A3 (en) Prevention and treatment of amyloidogenic disease
AU5714601A (en) Methods for prevention and treatment of gastrointestinal disorders
HUP0100627A3 (en) Prevention and treatment of amyloidogenic disease
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
AU7186501A (en) Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
AU4541101A (en) Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU9527001A (en) Treatment of T cell disorders
AUPQ622600A0 (en) Treatment and/or prevention of ocular pain
IL141211A0 (en) Prevention and treatment of viral disease
EP1356812A4 (en) Medicines for treatment and prevention of neurogenic pain
IL138692A0 (en) Treatment and prevention of vascular disease
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2000280405A1 (en) Targeting cells having mad2 mutation for treatment and/or prevention of disease
IL151019A0 (en) Microcompetition and human disease
EP1317271A4 (en) Therapeutic and cosmetic uses of heparanases
GB0012186D0 (en) Treatment of cancer and neurological diseases
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU2001233148A1 (en) Compositions of polygonum odoratum for prevention and treatment of disease
HUP0302882A3 (en) Improved specificity in treatment of diseases
AU2001245939A1 (en) Compositions and methods for the identification, assessment, prevention, and therapy of human cancers
GB0030866D0 (en) Treatment and prevention of disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 17, NO 32, PAGE(S) 11268 UNDER THE HEADING COMPLETE APPLICATIONS FILED - NAME INDEX DELETE ALL REFERENCE TO 2000280405

Free format text: IN VOL 17, NO 46, PAGE(S) 16152 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX DELETE ALL REFERENCE TO 2000280405

Free format text: IN VOL 18, NO 4, PAGE(S) 821 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN, PATENTS CEASED OR EXPIRED - 2000 DELETE ALL REFERENCE TO 2000280405